Minimal change nephrotic syndrome due to certolizumab pegol, an anti-tumor necrosis factor-alpha monoclonal antibody for treatment of rheumatoid arthritis
Rheumatol Adv Pract
.
2022 Feb 16;6(1):rkac012.
doi: 10.1093/rap/rkac012.
eCollection 2022.
Authors
Masafumi Sugiyama
1
2
,
Saki Okuda
1
,
Yasuaki Hirooka
1
Affiliations
1
Department of Rheumatology, Kindai University Nara Hospital, Nara.
2
Department of Rheumatology, Hashima Municipal Hospital, Gifu, Japan.
PMID:
35252744
PMCID:
PMC8892364
DOI:
10.1093/rap/rkac012
No abstract available